CTT Pharmaceutical Holdings’ CEO bought 10,100 shares at $0.04 each on 2026-09-22, taking the reported holding to 1,056,800 shares. The purchase represented about 1.0% of that resulting holding, giving investors a clear measure of the transaction against the reported post-purchase ownership position.
Key Highlights
- CTT Pharmaceutical Holdings’ purchase was recorded at $0.04 per share.
- The reported post-transaction position stood at 1,056,800 shares.
- Transaction code P identifies the entry as an open-market purchase representing about 1.0% of the resulting holding.
CTT PHARMACEUTICAL HOLDINGS, INC. (OTC: CTTH), identified in the transaction as its CEO, bought 10,100 shares at $0.04 per share on 22 September 2026. CTTH is a Pharmaceuticals: Major company.
The reported ownership position after the transaction was 1,056,800 shares. The acquired stake accounted for about 1.0% of that resulting total. The transaction identifies CTT PHARMACEUTICAL HOLDINGS, INC. As the buyer and labels the role CEO. The purchase price applies at $0.04 for each share acquired.
FAQs
Q: How many shares did CTT Pharmaceutical Holdings’ CEO buy?
A: CTT Pharmaceutical Holdings’ CEO bought 10,100 shares. The transaction took place on 22 September 2026 at $0.04 per share.
Q: What was CTT Pharmaceutical Holdings’ reported holding after the purchase?
A: The reported post-transaction holding was 1,056,800 shares. That figure includes the shares held after the purchase was completed.
Q: What does transaction code P mean for the CTTH share purchase?
A: The recorded purchase involved CTT Pharmaceutical Holdings shares at $0.04 per share.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.